ADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
